Adam Belley Selected Research

oritavancin

1/2018	Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
10/2017	Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.
2/2017	Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
1/2017	Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
1/2016	Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
1/2013	Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
12/2010	Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
6/2009	Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
10/2008	Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adam Belley Research Topics

Disease

11	Infections 01/2021 - 10/2008
2	Urinary Tract Infections (Urinary Tract Infection) 01/2020 - 01/2019
2	Body Weight (Weight, Body) 01/2020 - 01/2013
1	Healthcare-Associated Pneumonia 01/2020
1	Pneumonia (Pneumonitis) 01/2020
1	Pyelonephritis 01/2020
1	Thrombocytopenia (Thrombopenia) 01/2017
1	Activated Protein C Resistance (APC Resistance) 01/2017
1	Persistent Infection 01/2016

Drug/Important Bio-Agent (IBA)

9	oritavancinIBA 01/2018 - 10/2008
7	LipoglycopeptidesIBA 01/2018 - 10/2008
4	enmetazobactamIBA 01/2021 - 01/2019
4	Cefepime (Maxipime)FDA LinkGeneric 01/2021 - 01/2019
4	Vancomycin FDA LinkGeneric 01/2018 - 06/2009
4	Daptomycin FDA Link 01/2018 - 06/2009
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2018 - 01/2016
2	dalbavancinIBA 02/2017 - 01/2016
1	Carbapenems (Carbapenem Antibiotics)IBA 01/2021
1	beta-Lactamase InhibitorsIBA 01/2020
1	LipopeptidesIBA 01/2018
1	Ceftaroline FDA Link 02/2017
1	tedizolidIBA 02/2017
1	telavancin FDA Link 02/2017
1	Heparin (Liquaemin)FDA LinkGeneric 01/2017
1	Factor Xa (Coagulation Factor Xa)IBA 01/2017
1	Pharmaceutical PreparationsIBA 01/2013
1	TeicoplaninIBA 06/2009
1	Linezolid (Zyvox)FDA Link 06/2009

Therapy/Procedure

1	Therapeutics 01/2018